Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07806968
Starting soon Not applicable

Effect of Postural Correction Exercises on Pelvic Floor Dysfunction in Postmenopausal Osteoporotic Women

NCT07806968 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-09-08

Condition(s) studied

OsteoporosisPostmenopausal

Investigational drug(s) / intervention(s)

Estrogen replacement therapyGeneral advicePostural correction exercise program

Estrogen replacement therapy: The participants will receive estrogen replacement therapy for 3 months to enhance postmenopausal symptoms and their quality of life

General advice: Postmenopausal women will be instructed to maintain a neutral spinal alignment during sitting, standing, and daily activities, avoid prolonged slouched sitting, and use supportive seating to encourage correct posture. Light to moderate physical activity, such as daily walking, will be encouraged to reduce sedentary behavior and maintain overall physical function. women will also receive guidance on healthy bowel and bladder habits, including avoiding straining during bowel movements and unnecessary frequent urination, as increased intra-abdominal pressure can worsen pelvic floor dysfunction.

Postural correction exercise program: The participants will follow a structured postural correction exercise program, 3 times per week for 12 weeks, each session lasting 45-60 minutes.

Study summary

This study aimed to investigate the effect of postural correction exercises on pelvic floor dysfunction in postmenopausal osteoporotic women

Eligibility

Sex
FEMALE
Min age
55 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Postmenopausal women with ages between 55 and 65 years. * Their body mass index will not exceed 35 Kg/m2. * All women have mild to moderate pelvic floor muscle dysfunction. * All women were diagnosed with osteoporosis confirmed by Dual-energy X-ray Absorptiometry (DEXA) (T-score ≤ -2.5). Exclusion Criteria: * Women will be excluded if they have one or more of the following: * Previous pelvic or abdominal surgery affecting pelvic floor function. * Severe pelvic organ prolapse (Grade III or IV). * Neurological disorders affecting pelvic floor or lower limb function. * Severe musculoskeletal disorders limiting exercise participation. * Current participation in pelvic floor rehabilitation programs during the last 6 months. * Severe cardiovascular or respiratory conditions contraindicating exercise.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cairo university Giza Egypt

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07806968 on ClinicalTrials.gov ↗ ← All trials in Egypt